Director, CEO and President · RECURSION PHARMACEUTICALS, INC. · Class A Common Stock
Side
SELL
Value
$84K
Shares
23.6K
Price
$3.58
Executed
Jun 5, 2026
Disclosed
Jun 5, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Jun 5 executedJun 5, 2026 disclosed
RXRX · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering+15 / 15
3 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Khan Najat filed this Form 4 reporting a open-market sale of RXRX on Jun 5, 2026. It became public on Jun 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, CEO and President
Khan Najatcik:0002020969
Issuer
RECURSION PHARMACEUTICALS, INC.cik:0001601830
Revision history · 0
No field has changed since this record was first ingested.
